Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.8.0.1
Commitments and Contingencies (Details Textual) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2017
Mar. 31, 2017
Sep. 30, 2016
Mar. 31, 2016
Jun. 30, 2017
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Commitments And Contingencies [Line Items]                
Royalty Expense $ 200,000   $ 271,000     $ 593,000 $ 746,000  
Accrued Liabilities, Current 3,876,000         3,876,000   $ 5,224,000
Revenues 4,901,000   4,375,000     14,108,000 11,851,000  
Installment One [Member] | Two Thousand Fifteen MIST Therapy [Member]                
Commitments And Contingencies [Line Items]                
Revenues       $ 10,200,000        
Installment One [Member] | Two Thousand Fourteen MIST Therapy [Member]                
Commitments And Contingencies [Line Items]                
Revenues       $ 8,700,000        
Installment two [Member]                
Commitments And Contingencies [Line Items]                
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets   3.5            
Installment two [Member] | Two Thousand Fifteen MIST Therapy [Member]                
Commitments And Contingencies [Line Items]                
Revenues   $ 10,200,000            
Installment two [Member] | Two Thousand Sixteen MIST Therapy [Member]                
Commitments And Contingencies [Line Items]                
Revenues   10,500,000            
Human Longevity, Inc [Member]                
Commitments And Contingencies [Line Items]                
Royalty Expense 199,000   121,000     591,000 296,000  
Accrued Liabilities, Current 199,000   $ 197,000     199,000 $ 197,000  
Revenue Recognition, Milestone Method, Milestone Expenses           1,000,000    
Human Longevity, Inc [Member] | First Commercial Sale [Member]                
Commitments And Contingencies [Line Items]                
Contractual Obligation, Due in Next Twelve Months 500,000         500,000    
Human Longevity, Inc [Member] | Second Commercial Sale [Member]                
Commitments And Contingencies [Line Items]                
Contractual Obligation, Due in Next Twelve Months $ 500,000         $ 500,000    
Contingent Consideration [Member] | Installment One [Member]                
Commitments And Contingencies [Line Items]                
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets       3.5        
Payments to Acquire Businesses, Gross       $ 2,600,000        
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares       98,600        
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned       $ 2,600,000        
Contingent Consideration [Member] | Installment two [Member]                
Commitments And Contingencies [Line Items]                
Payments to Acquire Businesses, Gross   $ 675,000            
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares   100,000            
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned   $ 675,000            
Choice Therapeutics, Inc. [Member]                
Commitments And Contingencies [Line Items]                
Business Combination, Contingent Consideration, Liability         $ 500,000      
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares         130,000